[VIRTUAL] PHASE 1 TRIAL OF DURVALUMAB IN COMBINATION WITH BCG OR EXTERNAL BEAM RADIATION IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS (HCRN GU16-243: ADAPT-BLADDER TRIAL)

[VIRTUAL] ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (nmCRPC): STRIVE TRIAL EFFICACY AND SAFETY DATA

[VIRTUAL] LOW RATE OF CYSTECTOMY AND DELAYED MEDIAN TIME TO CYSTECTOMY AMONG PATIENTS WHO ACHIEVED COMPLETE RESPONSE WITH NADOFARAGENE FIRADENOVEC

[VIRTUAL] IMPACT OF LYMPHADENECTOMY ON THE RESPONSE TO SIPULEUCEL-T TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER

[VIRTUAL] SUBGROUP ANALYSES OF THE PHASE 3 STUDY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC IN PATIENTS WITH HIGH-GRADE, BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

[VIRTUAL] PHASE 2 MARKER LESION RESULTS FOR PROLIPOSOMAL PACLITAXEL (LIPAX) IN INTERMEDIATE RISK NMIBC

[VIRTUAL] Cytoreductive nephrectomy: are conclusions from the targeted therapy era valid in the checkpoint inhibitor era?

[VIRTUAL] NEOADJUVANT NIVOLUMAB IN PATIENTS WITH HIGH-RISK NON-METASTATIC RENAL CELL CARCINOMA

[VIRTUAL] GENOMIC PROFILING OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS FOR TREATMENT WITH RUCAPARIB: NEXT-GENERATION SEQUENCING OF CELL-FREE TUMOR DNA (CTDNA) AND TUMOR TISSUE

[VIRTUAL] ORAL HIF-2α INHIBITOR MK-6482 FOR VON HIPPEL-LINDAU (VHL) DISEASE–ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA: EVALUATION OF RCC AND NON-RCC DISEASE

[VIRTUAL] DURABILITY OF RESPONSE TO CHEMOABLATIVE TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA WITH A MITOMYCIN-CONTAINING REVERSE THERMAL HYDROGEL: FINAL RESULTS OF THE OLYMPUS TRIAL

[VIRTUAL] SIGNIFICANT ANTI-ADENOVIRUS ANTIBODY RESPONSE POSITIVELY CORRELATES WITH EFFICACY IN PATIENTS TREATED WITH NADOFARAGENE FIRADENOVEC FOR HIGH-GRADE BCG-UNRESPONSIVE NMIBC

[VIRTUAL] A PHASE 3, SINGLE-ARM STUDY OF CG0070 IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)